Evidence map›Paper›PMID 30210697›Full record

ArticleAmerican journal of translational research2018

Lithium chloride inhibits cell survival, overcomes drug resistance, and triggers apoptosis in multiple myeloma via activation of the Wnt/β-catenin pathway.

Ruosi Yao, Xiaoyang Sun, Yu Xie, Linlin Liu, Danyang Han, Yao Yao, Hujun Li, Zhenyu Li, Kailin Xu

Open access · greenAbstract read
In one paragraph

Article in American journal of translational research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Lithium: A Promising Anticancer Agent.Life (Basel, Switzerland) · 2023
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Bioactive Compounds fromOncoTargets and therapy · 2020
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Ruosi YaoBlood Diseases Institute, Xuzhou Medical University Xuzhou, Jiangsu, China.
Xiaoyang SunBlood Diseases Institute, Xuzhou Medical University Xuzhou, Jiangsu, China.
Yu XieBlood Diseases Institute, Xuzhou Medical University Xuzhou, Jiangsu, China.
Linlin LiuCollege of Medical Imaging, Xuzhou Medical University Xuzhou, Jiangsu, China.
Danyang HanBlood Diseases Institute, Xuzhou Medical University Xuzhou, Jiangsu, China.
Yao YaoBlood Diseases Institute, Xuzhou Medical University Xuzhou, Jiangsu, China.
Hujun LiDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University Xuzhou, Jiangsu, China.
Zhenyu LiBlood Diseases Institute, Xuzhou Medical University Xuzhou, Jiangsu, China.
Kailin XuBlood Diseases Institute, Xuzhou Medical University Xuzhou, Jiangsu, China.
Xuzhou Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma (MM) is an extremely malignant plasma cell disease, which is still incurable due to its drug resistance. Lithium chloride (LiCl) functions in many pathological processes, including bipolar disorder, acute brain injuries, and chronic neurodegenerative diseases, but its antagonistic role in MM progression has not been reported thus far. In this study, we found that LiCl inhibited MM cell proliferation and induced MM cell cycle G2/M phase arrest in a dose-dependent manner. Moreover, LiCl overcomes bortezomib (BTZ)-mediated resistance in MM cells and induces apoptosis in BTZ-resistant cells. Our data preliminarily indicate that LiCl induces MM cell apoptosis via activating the Wnt/β-catenin signaling pathway. Overall, our results define LiCl as an inducer of MM cell apoptosis and unveil a crosstalk between BTZ and LiCl in facilitating cell apoptosis.

Indexed as

apoptosisLithium chloridemultiple myelomaβ-catenin

Identifiers

PMID30210697
PMCPMC6129537
OpenAlexW2982545021

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.